Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05106049
  4. Details
NCT05106049 Clinical Trial

Serum Adiponectin as an Early Marker for Renal Impairment in Patients With Non-alcoholic Fatty Liver Disease.

Non-Alcoholic Fatty Liver Disease Clinical Trial

Official title:
Early Detection of Renal Impairment in Patients With Non-alcoholic Fatty Liver Disease by Measuring Serum Adiponectin Level.

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT05106049
Other study ID # Adiponectin in NAFLD
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date December 2021
Est. completion date January 2023

Study information
Verified date October 2021
Source Assiut University
Contact Hend Abdelrheem, Resident
Phone 01011062442
Email hendabdelrheem@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Early detection of renal impairment in patients with non-alcoholic fatty liver disease and its correlation with serum Adiponectin level.

Description:

Detection of serum Adiponectin by ELISA technique using (EIA-3418) KIT, DRG international inc., USA

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 90
Est. completion date January 2023
Est. primary completion date December 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Patients with fatty liver aged from 18 to 60 yrs either diabetic or not . - Patient with normal echogenic kidney in ultrasound and eGFR more than 60 mL/min/1.73m2. - The Control group are completely healthy subjects without any systemic or liver and kidney affection Exclusion Criteria: - Patients less than 18 yrs & more than 60 yrs . - All patients having any other causes of renal and hepatic disease rather than Diabetes and having any other systemic problem.

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• serum Adiponectin
serum adiponectin as early marker for renal impairment. Adiponectin is a recently identified adipose tissue-derived protein (adipocytokine) with important metabolic ,antiinflammatory, anti-atherogenic, and reactive oxygen species protective actions.

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Assiut University

References & Publications (1)

Stefan N, Stumvoll M. Adiponectin--its role in metabolism and beyond. Horm Metab Res. 2002 Sep;34(9):469-74. Review. — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary Correlate serum Adiponectin level with renal impairment in non-alcoholic fatty liver disease. measure level of serum Adiponectin in non-alcoholic fatty liver patients to detect early renal impairment. baseline
See also
  Status Clinical Trial Phase
Recruiting NCT05480696 - Soluble Fibre Supplementation in NAFLD Phase 1
Active, not recruiting NCT02500147 - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Phase 4
Completed NCT04671186 - Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan N/A
Recruiting NCT05979779 - Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis Phase 2
Recruiting NCT05462353 - Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH Phase 2
Completed NCT05006885 - ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD) Phase 1
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Recruiting NCT04365855 - The Olmsted NAFLD Epidemiology Study (TONES) N/A
Recruiting NCT05618626 - Prevention of NAFLD and CVD Through Lifestyle Intervention N/A
Completed NCT03256526 - 6-week Safety and PD Study in Adults With NAFLD Phase 2
Enrolling by invitation NCT06152991 - Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy Phase 3
Completed NCT03681457 - Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects Phase 1
Completed NCT06244550 - Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors N/A
Not yet recruiting NCT05120557 - Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH N/A
Completed NCT03060694 - Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
Completed NCT02526732 - Hepatic Inflammation and Physical Performance in Patients With NASH N/A
Recruiting NCT01988441 - The Influence of Autophagy on Fatty Liver
Recruiting NCT01680003 - Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease Phase 2
Completed NCT01712711 - Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease Phase 2
Recruiting NCT00941642 - Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Phase 4